SANIONA AB [CBOE] news, videos and press releases
For more news please use our advanced search feature.
SANIONA AB [CBOE] - More news...
SANIONA AB [CBOE] - More news...
- Saniona AB’s Nomination Committee for the Annual General Meeting 2023
- Saniona publishes its interim report for the third quarter of 2022
- Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies
- Saniona extends runway and amends loan agreement with Formue Nord
- Saniona publishes its interim report for the second quarter of 2022
- Bulletin from the Saniona AB extraordinary general meeting on August 18, 2022
- Saniona progresses its Kv7 epilepsy program into Lead Optimization
- Saniona provides update on outstanding option programs
- Notice of extraordinary general meeting in Saniona AB
- Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market
- Saniona reports positive top line results from the SAN711 Phase 1 Clinical Trial
- Saniona’s preclinical candidate SAN903 shows robust dampening of fibrosis in Chronic Kidney Disease model
- Bulletin from the Saniona AB annual shareholders’ meeting on May 25, 2022
- Saniona publishes its interim report for the first quarter of 2022
- Saniona´s Clinical Trial in Hypothalamic Obesity Published in Scientific Journal
- Saniona provides update on ongoing review of tesofensine in Mexico
- Saniona publishes its Annual Report for 2021
- Saniona Changes Date of Annual Report for 2021
- Notice of Saniona AB annual shareholders’ meeting
- Saniona Announces Refocused Strategy on Ion Channel R&D and Restructuring of Board of Directors and Executive Management Team
- Saniona Announces Strategic Program Prioritization and Restructuring to Streamline Operational Costs
- Saniona Initiates Positron Emission Tomography (PET) Stage of SAN711 Phase 1 Clinical Trial
- Saniona ion channel research collaboration with Boehringer Ingelheim advances to next stage
- Saniona to participate in multiple upcoming investor conferences
- Saniona publishes its year-end report for 2021
- Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial
- Saniona to participate in multiple upcoming virtual investor conferences
- Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome
- Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market
- Saniona AB’s Nomination Committee for the Annual General Meeting 2022